Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Gasparini

Showing results (21-30 of 355) with videos related to

Pageof 36
Sort By:
Neuropharmacology|September 7, 2001
Glutamate release inhibiting properties of the novel mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidenceL S Thomas, D E Jane, F Gasparini, et al.
Minerva Stomatologica|March 1, 1975
[Dental implantations of ceramics-coated metals]L Cini, F Gasparini, S Michieli, et al.
Behavioural Pharmacology|July 3, 2003
Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disordersW Spooren, T Ballard, F Gasparini, et al.
Neuropharmacology|July 11, 2001
The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in ratsB Schulz, M Fendt, F Gasparini, et al.
Journal of Clinical and Experimental Neuropsychology|June 1, 1997
The Post-Stroke Depression Rating Scale: a test specifically devised to investigate affective disorders of stroke patientsG Gainotti, A Azzoni, C Razzano, et al.
Headache|February 12, 2014
Genetic analysis of GRIA2 and GRIA4 genes in migraineClaudia F Gasparini, Heidi G Sutherland, Larisa M Haupt, et al.
Neuropharmacology|August 1, 1995
Pharmacological characterization of MCCG and MAP4 at the mGluR1b, mGluR2 and mGluR4a human metabotropic glutamate receptor subtypesT Knöpfel, S Lukic, T Leonard, et al.
British Journal of Pharmacology|August 24, 1999
Antagonism of the mGlu5 agonist 2-chloro-5-hydroxyphenylglycine by the novel selective mGlu5 antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) in the thalamusT E Salt, K E Binns, J P Turner, et al.
Neuropharmacology|January 16, 2003
The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activityS A Henry, V Lehmann-Masten, F Gasparini, et al.
Lancet (London, England)|March 30, 1985
Need for "deadaptation" of healthy research volunteers admitted to hospitalU Halbreich, G M Asnis, S Goldstein, et al.
Pageof 36

Showing results (21-30 of 355) with videos related to

Sort By:
Pageof 36
Neuropharmacology|September 7, 2001
Glutamate release inhibiting properties of the novel mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidenceL S Thomas, D E Jane, F Gasparini, et al.
Minerva Stomatologica|March 1, 1975
[Dental implantations of ceramics-coated metals]L Cini, F Gasparini, S Michieli, et al.
Behavioural Pharmacology|July 3, 2003
Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disordersW Spooren, T Ballard, F Gasparini, et al.
Neuropharmacology|July 11, 2001
The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in ratsB Schulz, M Fendt, F Gasparini, et al.
Journal of Clinical and Experimental Neuropsychology|June 1, 1997
The Post-Stroke Depression Rating Scale: a test specifically devised to investigate affective disorders of stroke patientsG Gainotti, A Azzoni, C Razzano, et al.
Headache|February 12, 2014
Genetic analysis of GRIA2 and GRIA4 genes in migraineClaudia F Gasparini, Heidi G Sutherland, Larisa M Haupt, et al.
Neuropharmacology|August 1, 1995
Pharmacological characterization of MCCG and MAP4 at the mGluR1b, mGluR2 and mGluR4a human metabotropic glutamate receptor subtypesT Knöpfel, S Lukic, T Leonard, et al.
British Journal of Pharmacology|August 24, 1999
Antagonism of the mGlu5 agonist 2-chloro-5-hydroxyphenylglycine by the novel selective mGlu5 antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) in the thalamusT E Salt, K E Binns, J P Turner, et al.
Neuropharmacology|January 16, 2003
The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activityS A Henry, V Lehmann-Masten, F Gasparini, et al.
Lancet (London, England)|March 30, 1985
Need for "deadaptation" of healthy research volunteers admitted to hospitalU Halbreich, G M Asnis, S Goldstein, et al.
Pageof 36